Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Net Cash Flow (2016 - 2025)

Vistagen Therapeutics' Net Cash Flow history spans 14 years, with the latest figure at -$15.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 61.79% year-over-year to -$15.4 million; the TTM value through Dec 2025 reached -$27.3 million, up 47.25%, while the annual FY2025 figure was -$52.0 million, 150.75% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$15.4 million at Vistagen Therapeutics, down from $13.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $89.0 million in Q4 2023 and bottomed at -$18.7 million in Q3 2024.
  • The 4-year median for Net Cash Flow is -$7.6 million (2025), against an average of -$1.0 million.
  • The largest annual shift saw Net Cash Flow crashed 2894.23% in 2021 before it surged 173.69% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$9.5 million in 2021, then skyrocketed by 1038.19% to $89.0 million in 2023, then plummeted by 110.71% to -$9.5 million in 2024, then plummeted by 61.79% to -$15.4 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Net Cash Flow are -$15.4 million (Q4 2025), $13.8 million (Q3 2025), and -$18.1 million (Q2 2025).